Pasar al contenido principal

TITULO DEL PROYECTO COORDINADO (ACRONIMO): PATOGENESIS PLACENTARIA DE BRUCELLA Y DESARROLLO DE VACUNAS DESDE UNA NUEVA PERSPECTIVA MOLECULAR EN BRUCELOSIS

PID2022-139200OB-C21

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Brucella melitensis Rev1Δwzm: Placental pathogenesis studies and safety in pregnant ewes

  • Poveda-Urkixo, Irati
  • Mena-Bueno, S.
  • Ramírez, Gustavo A.
  • Zabalza-Baranguá, A.
  • Tsolis, Renee M.
  • Grilló, María Jesús
One of the main causes of human brucellosis is Brucella melitensis infecting small ruminants. To date, Rev1 is the only vaccine successfully used to control ovine and caprine brucellosis. However, it is pathogenic for pregnant animals, resulting in abortions and vaginal and milk shedding, as well as being infectious for humans. Therefore, there is an urgent need to develop an effective vaccine that is safer than Rev1. In efforts to further attenuate Rev1, we recently used wzm inactivation to generate a rough mutant (Rev1Δwzm) that retains a complete antigenic O-polysaccharide in the bacterial cytoplasm. The aim of the present study was to evaluate the placental pathogenicity of Rev1Δwzm in trophoblastic cells, throughout pregnancy in mice, and in ewes inoculated in different trimesters of pregnancy. This mutant was evaluated in comparison with the homologous 16MΔwzm derived from a virulent strain of B. melitensis and the naturally rough sheep pathogen B. ovis. Our results show that both wzm mutants triggered reduced cytotoxic, pro-apoptotic, and pro-inflammatory signaling in Bewo trophoblasts, as well as reduced relative expression of apoptosis genes. In mice, both wzm mutants produced infection but were rapidly cleared from the placenta, in which only Rev1Δwzm induced a low relative expression of pro-apoptotic and pro-inflammatory genes. In the 66 inoculated ewes, Rev1Δwzm was safe and immunogenic, displaying a transient serological interference in standard RBT but not CFT S-LPS tests; this serological response was minimized by conjunctival administration. In conclusion, these results support that B. melitensis Rev1Δwzm is a promising vaccine candidate for use in pregnant ewes and its efficacy against B. melitensis and B. ovis infections in sheep warrants further study., This work was funded by Agencia Estatal de Investigacion ´ of the Ministerio de Ciencia, Innovacion ´ y Universidades (RTI2018-098658-BC21 and PID2022-139200OB-C21) and Gobierno de Navarra (PT040- 2018 and PT007-2019) research projects. IPU’s contract was granted by the Doctorados Industriales program of the Navarra government (2017–2019), cofounded by CSIC. SMB’s contracts were granted by the Garantía Juvenil CSIC-FEDER program (2016–2018) and by an UPNA pre-doctoral fellowship (2018–2022)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Brucella melitensis Rev1Δwzm: placental pathogenesis studies and safety in pregnant ewes

  • Poveda-Urkixo, Irati
  • Mena-Bueno, Sara
  • Ramírez, Gustavo A.
  • Zabalza-Baranguá, Ana
  • Tsolis, Renee M.
  • Grilló, María Jesús
One of the main causes of human brucellosis is Brucella melitensis infecting small ruminants. To date, Rev1 is the only vaccine successfully used to control ovine and caprine brucellosis. However, it is pathogenic for pregnant animals, resulting in abortions and vaginal and milk shedding, as well as being infectious for humans. Therefore, there is an urgent need to develop an effective vaccine that is safer than Rev1. In efforts to further attenuate Rev1, we recently used wzm inactivation to generate a rough mutant (Rev1Δwzm) that retains a complete antigenic O-polysaccharide in the bacterial cytoplasm. The aim of the present study was to evaluate the placental pathogenicity of Rev1Δwzm in trophoblastic cells, throughout pregnancy in mice, and in ewes inoculated in different trimesters of pregnancy. This mutant was evaluated in comparison with the homologous 16M∆wzm derived from a virulent strain of B. melitensis and the naturally rough sheep pathogen B. ovis. Our results show that both wzm mutants triggered reduced cytotoxic, pro-apoptotic, and pro-inflammatory signaling in Bewo trophoblasts, as well as reduced relative expression of apoptosis genes. In mice, both wzm mutants produced infection but were rapidly cleared from the placenta, in which only Rev1Δwzm induced a low relative expression of pro-apoptotic and pro-inflammatory genes. In the 66 inoculated ewes, Rev1Δwzm was safe and immunogenic, displaying a transient serological interference in standard RBT but not CFT S-LPS tests; this serological response was minimized by conjunctival administration. In conclusion, these results support that B. melitensis Rev1Δwzm is a promising vaccine candidate for use in pregnant ewes and its efficacy against B. melitensis and B. ovis infections in sheep warrants further study., This work was funded by Agencia Estatal de Investigación of the Ministerio de Ciencia, Innovación y Universidades (RTI2018-098658-B-C21 and PID2022-139200OB-C21) and Gobierno de Navarra (PT040-2018 and PT007-2019) research projects. IPU’s contract was granted by the Doctorados Industriales program of the Navarra government (2017-2019), cofounded by CSIC. SMB’s contracts were granted by the Garantía Juvenil CSIC-FEDER program (2016-2018) and by an UPNA pre-doctoral fellowship (2018–2022). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Rev1Δwzm vaccine candidate is safe in young and adult sheep and protects against Brucella ovis infection in rams

  • Mena-Bueno, Sara
  • Garrido, Victoria
  • Romero, Francisco
  • Zabalza-Baranguá, Ana
  • Grilló, María Jesús
Small ruminants affected by brucellosis, caused mainly by Brucella melitensis and B. ovis, suffer reproductive disorders, leading to significant economic losses worldwide. Vaccination is an essential tool to prevent the disease in ovine and caprine livestock, but the only vaccine recommended to date is B. melitensis Rev1, which in sheep is only safe for use in lambs aged 3–4 months. This restriction poses considerable practical challenges for the implementation of Rev1 in countries with endemic brucellosis and/or limited resources, where there is a need for mass vaccination with a safe vaccine to control the disease in both animals and humans. We recently developed a B. melitensis strain Rev1Δwzm showing superior vaccine properties in mice and safety in pregnant ewes. Here, we report that Rev1Δwzm (i) is safe in young and adult sheep, both male and female; (ii) induces a transient serological response in the Rose Bengal test in ≤50 % of sheep, confirmed to some extent by the complement fixation test, and a stronger, more persistent anti- rough-LPS response; and (iii) protects rams against a B. ovis challenge 25 weeks after vaccination. To resolve the problem of serological interference, the use of green fluorescent protein tagging strategy allowed us to identify vaccinated sheep with only a single inoculation. These results, together with the previously reported safety in pregnant ewes, position Rev1Δwzm as a firm vaccine candidate and a promising alternative to Rev1. Further experiments are warranted to assess its efficacy against B. melitensis in pregnant ewes., This work was funded by Agencia Estatal de Investigación of the Ministerio de Ciencia, Innovación y Universidades (RTI2018-098658-B-C21 and PID2022-139200OB-C21) and Gobierno de Navarra (PT040-2018 and PT007-2019) projects. SMB contract was granted by an UPNA pre-doctoral fellowship 2018–2022., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Brucella melitensis Rev1Δwzm: Placental pathogenesis studies and safety in pregnant ewes

  • Poveda-Urkixo, Irati
  • Mena-Bueno, S.
  • Ramírez, Gustavo A.
  • Zabalza-Baranguá, A.
  • Tsolis, Renee M.
  • Grilló, María Jesús
One of the main causes of human brucellosis is Brucella melitensis infecting small ruminants. To date, Rev1 is the only vaccine successfully used to control ovine and caprine brucellosis. However, it is pathogenic for pregnant animals, resulting in abortions and vaginal and milk shedding, as well as being infectious for humans. Therefore, there is an urgent need to develop an effective vaccine that is safer than Rev1. In efforts to further attenuate Rev1, we recently used wzm inactivation to generate a rough mutant (Rev1Δwzm) that retains a complete antigenic O-polysaccharide in the bacterial cytoplasm. The aim of the present study was to evaluate the placental pathogenicity of Rev1Δwzm in trophoblastic cells, throughout pregnancy in mice, and in ewes inoculated in different trimesters of pregnancy. This mutant was evaluated in comparison with the homologous 16MΔwzm derived from a virulent strain of B. melitensis and the naturally rough sheep pathogen B. ovis. Our results show that both wzm mutants triggered reduced cytotoxic, pro-apoptotic, and pro-inflammatory signaling in Bewo trophoblasts, as well as reduced relative expression of apoptosis genes. In mice, both wzm mutants produced infection but were rapidly cleared from the placenta, in which only Rev1Δwzm induced a low relative expression of pro-apoptotic and pro-inflammatory genes. In the 66 inoculated ewes, Rev1Δwzm was safe and immunogenic, displaying a transient serological interference in standard RBT but not CFT S-LPS tests; this serological response was minimized by conjunctival administration. In conclusion, these results support that B. melitensis Rev1Δwzm is a promising vaccine candidate for use in pregnant ewes and its efficacy against B. melitensis and B. ovis infections in sheep warrants further study., This work was funded by Agencia Estatal de Investigacion ´ of the Ministerio de Ciencia, Innovacion ´ y Universidades (RTI2018-098658-BC21 and PID2022-139200OB-C21) and Gobierno de Navarra (PT040- 2018 and PT007-2019) research projects. IPU’s contract was granted by the Doctorados Industriales program of the Navarra government (2017–2019), cofounded by CSIC. SMB’s contracts were granted by the Garantía Juvenil CSIC-FEDER program (2016–2018) and by an UPNA pre-doctoral fellowship (2018–2022)